In a massive stride towards Alzheimer’s treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer’s ...
POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity ...
POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (“IGC Pharma” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, announced today that Divisional Direction of Patents, ...
Based on these signals, we are initiating a larger efficacy trial to test IGC-AD1 as a symptom modifying agent, specifically on agitation in dementia due to Alzheimer’s disease. The Company recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results